| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Khanh-Hoang Nguyen | Q86493620 |
| Dinh-Toi Chu | Q41647914 | ||
| Deepak B Thimiri Govinda Raj | Q61133617 | ||
| P2093 | author name string | Vo Truong Nhu Ngoc | |
| Vu Thi Nga | |||
| Nguyen Duy Bac | |||
| Duong Thi Anh Dao | |||
| Le Ngoc Hoan | |||
| Le Nguyen Vu | |||
| Nguyen Le Bao Tien | |||
| Nguyen Phuc Hung | |||
| Nguyen Thi Trung Thu | |||
| Thuy Anh Vu Pham | |||
| Van-Huy Pham | |||
| Vo Van Thanh | |||
| P2860 | cites work | Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity | Q78346730 |
| Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment | Q79342882 | ||
| Mouse dendritic-endothelial cell hybrids and 4-1BB costimulation elicit antitumor effects mediated by broad antiangiogenic immunity | Q80798131 | ||
| Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines | Q81019091 | ||
| Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy | Q81310257 | ||
| Integrative Pharmacology: Advancing Development of Effective Immunotherapies | Q88499080 | ||
| Molecular and biological characterization of human 4-1BB and its ligand | Q24320045 | ||
| A receptor induced by lymphocyte activation (ILA): a new member of the human nerve-growth-factor/tumor-necrosis-factor receptor family | Q24322784 | ||
| cDNA sequences of two inducible T-cell genes | Q24621040 | ||
| Routes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in mice | Q27335400 | ||
| 4-1BB agonism: adding the accelerator to cancer immunotherapy | Q28079622 | ||
| The TNF and TNF receptor superfamilies: integrating mammalian biology | Q28203717 | ||
| Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy | Q28235277 | ||
| A link between inflammation and metastasis: serum amyloid A1 and A3 induce metastasis, and are targets of metastasis-inducing S100A4 | Q28306743 | ||
| Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin | Q28537820 | ||
| A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis | Q28588558 | ||
| Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies | Q28656460 | ||
| Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production | Q28740530 | ||
| Therapeutic potential of anti-CD137 (4-1BB) monoclonal antibodies | Q33426409 | ||
| The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors | Q33595085 | ||
| CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells | Q33722711 | ||
| Targeting CD137 enhances the efficacy of cetuximab. | Q33872482 | ||
| Invariant natural killer T cells regulate anti-tumor immunity by controlling the population of dendritic cells in tumor and draining lymph nodes | Q34389948 | ||
| Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy | Q34656292 | ||
| CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies | Q34707604 | ||
| The availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies | Q34778826 | ||
| Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. | Q39602916 | ||
| Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. | Q40092180 | ||
| Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. | Q40571610 | ||
| 4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-mu-primed splenic B cells | Q41489234 | ||
| Involvement of the 4-1BB/4-1BBL pathway in control of monocyte numbers by invariant NKT cells | Q42230745 | ||
| The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment | Q43215888 | ||
| Immunotherapy targeting 4-1BB and its ligand | Q44011524 | ||
| 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. | Q44187638 | ||
| Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation | Q45869327 | ||
| NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation | Q45873342 | ||
| Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types | Q46537519 | ||
| Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors | Q46612674 | ||
| Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice | Q46686977 | ||
| Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity | Q47203993 | ||
| Extracellular S100A4(mts1) stimulates invasive growth of mouse endothelial cells and modulates MMP-13 matrix metalloproteinase activity | Q47662103 | ||
| Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies | Q47790828 | ||
| Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies | Q47850855 | ||
| Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression | Q47950137 | ||
| Therapeutic Efficacy of 4-1BB Costimulation Is Abrogated by PD-1 Blockade in a Model of Spontaneous B-cell Lymphoma | Q48859366 | ||
| Increased diversity with reduced "diversity evenness" of tumor infiltrating T-cells for the successful cancer immunotherapy | Q49698755 | ||
| Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer. | Q51738252 | ||
| S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity. | Q52597566 | ||
| Cancer immunotherapy using checkpoint blockade. | Q52641912 | ||
| Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer. | Q52651310 | ||
| Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers. | Q53235785 | ||
| NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. | Q54109907 | ||
| Detection of the TNFSF members BAFF, APRIL, TWEAK and their receptors in normal kidney and renal cell carcinomas. | Q54315145 | ||
| Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity | Q56902023 | ||
| Cancer immunologists scoop medicine Nobel prize | Q57060291 | ||
| Therapeutic vaccination with 4-1BB co-stimulation eradicates mouse acute myeloid leukemia | Q57138588 | ||
| Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab | Q58586476 | ||
| The HIF-1α Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy | Q59415963 | ||
| Inducible T cell antigen 4-1BB. Analysis of expression and function | Q72068154 | ||
| Role of TNF receptor-associated factor 2 and p38 mitogen-activated protein kinase activation during 4-1BB-dependent immune response | Q73209264 | ||
| Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal | Q77399210 | ||
| A co-evolution perspective of the TNFSF and TNFRSF families in the immune system | Q35177717 | ||
| Agonist antibodies to TNFR molecules that costimulate T and NK cells | Q35427446 | ||
| NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma | Q35506745 | ||
| Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer | Q35780315 | ||
| TNF superfamily in inflammatory disease: translating basic insights | Q35821666 | ||
| Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12. | Q36220613 | ||
| 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses | Q36380273 | ||
| Host immunity contributes to the anti-melanoma activity of BRAF inhibitors | Q36638192 | ||
| Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. | Q36675055 | ||
| Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation | Q36936462 | ||
| Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma | Q36975064 | ||
| Expression of anti-HVEM single-chain antibody on tumor cells induces tumor-specific immunity with long-term memory. | Q37102329 | ||
| Structural basis of signal transduction in the TNF receptor superfamily | Q37194681 | ||
| The role of TNF superfamily members in T-cell function and diseases | Q37332068 | ||
| Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer | Q37368087 | ||
| Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion | Q37396078 | ||
| Combination immune therapies to enhance anti-tumor responses by NK cells. | Q37408550 | ||
| Human and mouse CD137 have predominantly different binding CRDs to their respective ligands | Q37500368 | ||
| Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses. | Q37574566 | ||
| T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy | Q37948129 | ||
| Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. | Q38004628 | ||
| Immunotherapy of cancer with 4-1BB. | Q38005370 | ||
| High expression of APRIL correlates with poor prognosis in clear cell renal cell carcinoma | Q38423172 | ||
| Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. | Q38440279 | ||
| Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb | Q38758452 | ||
| S100A4 promotes liver fibrosis via activation of hepatic stellate cells | Q38967195 | ||
| The curative outcome of radioimmunotherapy in a mouse breast cancer model relies on mTOR signaling | Q38981688 | ||
| The role of CD30 and CD153 (CD30L) in the anti-mycobacterial immune response | Q39070848 | ||
| Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. | Q39096595 | ||
| T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes. | Q39149430 | ||
| Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody | Q39274485 | ||
| Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity | Q39381907 | ||
| Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer | Q39399821 | ||
| Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. | Q39457367 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | targeted therapy | Q492646 |
| neoplasm | Q1216998 | ||
| immunotherapy | Q1427096 | ||
| immunological antineoplastic agent | Q50429626 | ||
| P304 | page(s) | 1822 | |
| P577 | publication date | 2019-04-12 | |
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer | |
| P478 | volume | 20 |
| Q94464383 | CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers |
| Q89750449 | Class A CpG oligodeoxynucleotide inhibits IFN-γ-induced signaling and apoptosis in lung cancer |
| Q91942447 | Dual Pro- and Anti-Inflammatory Features of Monocyte-Derived Dendritic Cells |
| Q99552013 | The role of trogocytosis in immune surveillance of Hodgkin lymphoma |
| Q89690681 | Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma |
Search more.